A Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Subjects with Sickle Cell Disease

Administered By

Medicine, Hematology

Awarded By

Global Blood Therapeutics, Inc.

Contributors

Shah, Nirmish Ramesh Principal Investigator

Start/End

May 17, 2017 - April 30, 2022